Atara Biotherapeutics (ATRA) Other Operating Expenses (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Other Operating Expenses came in at $124000.0 in Q1 2026, down 99.39% YoY from $20.4 million in Q1 2025, and up 19.23% on a QoQ basis from $104000.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Other Operating Expenses (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 9 years of Other Operating Expenses data on file, last reported at $124000.0 in Q1 2026.
- Quarterly Other Operating Expenses fell 99.39% year-over-year to $124000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $897000.0 (down 97.73% YoY) and the FY2025 annual result came in at $21.2 million, up 0.97% from the prior year.
- Other Operating Expenses advanced to $124000.0 in Q1 2026, from $104000.0 in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $50.2 million in Q2 2022 to a low of $104000.0 in Q4 2025.
- A 5-year average of $8.4 million and a median of $2.0 million in 2024 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2025 — Other Operating Expenses surged 929.67% — and 2026, when it tumbled 99.39%.
- Tracing ATRA's Other Operating Expenses over 5 years: stood at $50.2 million in 2022, then plunged by 99.57% to $216000.0 in 2023, then surged by 3045.83% to $6.8 million in 2024, then tumbled by 98.47% to $104000.0 in 2025, then grew by 19.23% to $124000.0 in 2026.
- The last three Other Operating Expenses figures came in at $124000.0 (Q1 2026), $104000.0 (Q4 2025), and $115000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 191,000.00 |
| Mar 31, 2026 | 124,000.00 |
| Dec 31, 2025 | 104,000.00 |
| Sep 30, 2025 | 115,000.00 |
| Jun 30, 2025 | 554,000.00 |
| Mar 31, 2025 | 20.44 Mn |
| Dec 31, 2024 | 6.80 Mn |
| Sep 30, 2024 | 7.60 Mn |
| Jun 30, 2024 | 4.63 Mn |
| Mar 31, 2024 | 1.99 Mn |
| Mar 31, 2023 | 216,000.00 |
| Jun 30, 2022 | 50.24 Mn |
| Dec 31, 2018 | 49.76 Mn |
| Sep 30, 2016 | 15.50 Mn |
| Dec 31, 2014 | -1.07 Mn |
| Sep 30, 2014 | 2.24 Mn |
| Jun 30, 2014 | 1.07 Mn |
| Dec 31, 2013 | 3,000.00 |
| Sep 30, 2013 | 550,000.00 |